Kingston Wire, October 23, 2023: NCHR president Diana Zuckerman’s oped in the Kingston (NY) Wire explains the risks to children of lead and other toxic chemicals in PIP rubber playground surfaces and artificial turf in Kingston and other communities.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Experts fear FDA push to get neurological drugs to market faster shortchanges patients
Politico Pro, October 20, 2023: Politico news story explains that FDA’s accelerated approval of neurological drugs shortchanges patients who have lobbied for it because these very expensive drugs aren’t proven to work
Read More »Inside the NFL turf debate: Injuries, safety measures, problems
ESPN, October 11, 2023: This comprehensive ESPN news article explains the NFL injury rate and players’ concerns comparing grass fields to artificial turf. Diana Zuckerman tells ESPN reporters about biased info from artificial turf industry.
Read More »Consumer and Public Health Groups Support FDA Proposal to Ensure Accuracy of Lab-Developed Medical Tests
September 29, 2023: A coalition of consumer advocacy groups is welcoming a proposed rule released today by the Food and Drug Administration to regulate laboratory-developed tests (LDTs), a category of diagnostic tests developed and used in a single lab.
Read More »Who gets to decide who receives experimental medical treatments?
MIT Technology Review, August 10, 2023: This excellent news article by MIT Technology Review asks “Who decides who receives experimental medical treatments” and are FDA’s standards for accelerated approval too low for Duchenne Muscular Dystrophy, cancer, and other diseases. We call accelerated approval a disaster.
Read More »